Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.

Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D.

Neurology. 2013 Mar 26;80(13):1251-60. doi: 10.1212/WNL.0b013e318289703b. Epub 2013 Mar 13. Review.

PMID:
23486879
2.

Addressing the problem of ADHD medication as neuroenhancements.

Graf WD, Miller G, Nagel SK.

Expert Rev Neurother. 2014 May;14(5):569-81. doi: 10.1586/14737175.2014.908707. Epub 2014 Apr 17. Review.

PMID:
24738763
3.

Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians.

Singh I, Filipe AM, Bard I, Bergey M, Baker L.

Curr Psychiatry Rep. 2013 Sep;15(9):385. doi: 10.1007/s11920-013-0385-0. Review.

PMID:
23933975
4.

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R.

Can J Cardiol. 2009 Nov;25(11):625-30. Review.

6.

Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Wigal SB.

CNS Drugs. 2009;23 Suppl 1:21-31. doi: 10.2165/00023210-200923000-00004. Review.

PMID:
19621975
7.

The ethics of neuroenhancement.

Chatterjee A.

Handb Clin Neurol. 2013;118:323-34. doi: 10.1016/B978-0-444-53501-6.00027-5. Review.

PMID:
24182389
8.

Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).

[No authors listed]

NIH Consens Statement. 1998 Nov 16-18;16(2):1-37. Review.

PMID:
10868163
9.

Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.

Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S.

J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31. doi: 10.1097/chi.0b013e31815a56f1. Review.

PMID:
18174822
10.

Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.

Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.

J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90. doi: 10.1016/j.jaac.2011.07.018. Epub 2011 Sep 3. Review.

PMID:
21961773
11.

The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s.

Diller LH.

Hastings Cent Rep. 1996 Mar-Apr;26(2):12-8. Review. No abstract available.

PMID:
8722521
12.

Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.

Rapoport JL, Inoff-Germain G.

J Atten Disord. 2002;6 Suppl 1:S57-60. Review.

PMID:
12685519
13.

Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.

Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML; American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder.

Pediatrics. 2005 Jun;115(6):e749-57. Review.

PMID:
15930203
14.

Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.

Mohammadi M, Akhondzadeh S.

Acta Med Iran. 2011;49(8):487-98. Review.

15.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
16.

ADHD in children, adolescents, and adults.

Katragadda S, Schubiner H.

Prim Care. 2007 Jun;34(2):317-41; abstract viii. Review.

PMID:
17666230
17.

Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.

Rader R, McCauley L, Callen EC.

Am Fam Physician. 2009 Apr 15;79(8):657-65. Review.

18.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
19.

Are stimulants overprescribed for youths with ADHD?

Safer DJ.

Ann Clin Psychiatry. 2000 Mar;12(1):55-62. Review.

PMID:
10798827
20.

Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.

Noorbala AA, Akhondzadeh S.

Arch Iran Med. 2006 Oct;9(4):374-80. Review.

PMID:
17061613
Items per page

Supplemental Content

Write to the Help Desk